首页 | 本学科首页   官方微博 | 高级检索  
检索        

肝癌选择性溶瘤腺病毒的构建及其体外抑瘤作用
引用本文:傅 强,王慧萍,韦 芳,李慧明,陈霞芳,王煜非,黄 倩.肝癌选择性溶瘤腺病毒的构建及其体外抑瘤作用[J].中国肿瘤生物治疗杂志,2009,16(2):113-119.
作者姓名:傅 强  王慧萍  韦 芳  李慧明  陈霞芳  王煜非  黄 倩
作者单位:上海交通大学医学院,附属上海市第一人民医院,中心实验室,上海,200080
基金项目:国家重点基础研究计划(973)资助项目 (No.2004CB518804);国家自然科学基金杰出青年项目 (No.30325043)
摘    要:目的: 构建由AFP基因增强子启动子调控,并携带自杀基因TK的新型条件复制型腺病毒载体,观察该载体的选择复制能力、溶瘤作用及其与前药GCV联合处理对肝癌细胞的杀伤作用。方法:以HepG2基因组DNA为模板,PCR扩增AFP基因启动子(AFPp)和增强子(AFPe),构建表达质粒pAFPpEGFPluc和pAFPepEGFPluc,再构建由AFPep调控E1A表达、并携带TK基因的穿梭质粒pDC311AFPepE1A/CMVTK,利用AdMax系统包装腺病毒Ad.AFPepE1A/CMVTK;利用Western blotting、病毒增殖测试、细胞病变效应实验、病毒联合前药GCV对肝癌细胞的杀伤实验等鉴定病毒的复制能力、溶瘤作用和对肝癌细胞的杀伤作用。结果:成功构建的腺病毒载体 Ad.AFPepE1A/CMVTK在AFP阳性细胞中选择性复制,病毒自身具有一定的溶瘤作用;该病毒载体联合GCV前药系统处理肝癌细胞后,AFP阳性肝癌HepG2细胞和Hep3B细胞的存活率分别为(10.35±1.07)%、(15.49±5.80)%,AFP阴性的张氏肝细胞和人肺癌NCIH460细胞的存活率分别为(73.55±436)%、(74.54±9.89)% (P<0.01)。结论:构建的新型溶瘤腺病毒载体具有选择性杀伤肝癌细胞的能力,在肝癌治疗方面有良好的应用前景。

关 键 词:肝肿瘤  条件复制型腺病毒载体  HSV-1TK基因  甲胎蛋白基因启动子  甲胎蛋白基因增强子  病毒-基因治疗
收稿时间:2009/2/24 0:00:00
修稿时间:2009/3/17 0:00:00

Construction of conditionally replication-competent adenoviral vectors targeting hepatocarcinoma and their in vitro anti-tumor effect
FU Qiang,WANG Hui ping,WEI Fang,LI Hui ming,CHEN Xia fang,WANG Yi fei and HUANG Qian.Construction of conditionally replication-competent adenoviral vectors targeting hepatocarcinoma and their in vitro anti-tumor effect[J].Chinese Journal of Cancer Biotherapy,2009,16(2):113-119.
Authors:FU Qiang  WANG Hui ping  WEI Fang  LI Hui ming  CHEN Xia fang  WANG Yi fei and HUANG Qian
Institution:Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China;Central Lab, The First People's Hospital of Shanghai, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China
Abstract:
Keywords:
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《中国肿瘤生物治疗杂志》浏览原始摘要信息
点击此处可从《中国肿瘤生物治疗杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号